Materias dentro de su búsqueda.
Mostrando 101 - 120 Resultados de 110,380 Para Buscar '"Lu'an"', tiempo de consulta: 1.61s Limitar resultados
  1. 101
    “…Here we show that increasing cholesterol levels are associated with peripheral monocyte depletion and this imbalance is aggravated by carriage of Lu/BCAM leukocyte adhesion molecules. This is true only in HIV infection and probably explains the risk of atherosclerosis observed in HIV-positive patients.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Potential role of Lu/BCAM in HIV-related atherosclerosis
  2. 102
    Publicado 2021
    “…Manh Tin Ho and Jiongming Lu are co-first authors on ‘A translation-independent activity of PheRS activates growth and proliferation in Drosophila’, published in DMM. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    First person – Manh Tin Ho and Jiongming Lu
  3. 103
    por Keam, Susan J.
    Publicado 2022
    “…Lutetium Lu 177 vipivotide tetraxetan (PLUVICTO™, formerly known as (177)Lu-PSMA-617) is a radioligand therapeutic agent that is being developed by Advanced Accelerator Applications (a subsidiary of Novartis) for the treatment of prostate-specific membrane antigen (PSMA)-expressing metastatic prostate cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Lutetium Lu 177 Vipivotide Tetraxetan: First Approval
  4. 104
    “…From an experiment performed at the muon-channel of the CERN Synchrocyclotron with a parasitic beam, the authors have observed the quadrupole splitting of the 4f-3d X-ray transition in muonic /sup 175/Lu. A preliminary evaluation of the data gives a nuclear spectroscopic quadrupole moment of the ground state of /sup 175/Lu, Q=3.46+or-0.06 b. …”
    Enlace del recurso
    Determination of nuclear spectroscopic quadrupole moment from muonic /sup 175/Lu and observation of quadrupole-hyperfine splitting in pionic /sup 175/Lu
  5. 105
    “…METHODS: Patients with gastro-entero-pancreatic (GEP) NEN who received LuTate followed by quantitative SPECT/CT (Q-SPECT/CT) the next day (Jul 2010 to Jan 2019) were retrospectively reviewed. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with (177)Lu DOTATATE (LuTate)
  6. 106
    “…PURPOSE: While there are reports of treatment-related endocrine disruptions and catecholamine surges in pheochromocytoma/paraganglioma (PPGL) patients treated with [(177)Lu]Lu-DOTA-TATE therapy, the spectrum of these abnormalities in the immediate post-treatment period (within 48 hours) has not been previously evaluated and is likely underestimated. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [(177)Lu]Lu-DOTA-TATE therapy
  7. 107
    “…PURPOSE: We present the results of an open-label, phase I/II study evaluating the safety and efficacy of the novel somatostatin receptor (SSTR) antagonist [(177)Lu]Lu-satoreotide tetraxetan in 40 patients with previously treated, progressive neuroendocrine tumours (NETs), in which dosimetry was used to guide maximum administered activity. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A phase I/II study of the safety and efficacy of [(177)Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours
  8. 108
    “…Both RAD001 and [(177)Lu]Lu-PP-F11N single treatments as well as their combination inhibited tumor growth and increased survival. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [(177)Lu]Lu-PP-F11N
  9. 109
    “…[(177)Lu]Lu-PSMA radioligand therapy (PSMA-RLT) is a promising therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) and offers a survival benefit particularly to patients with only lymph node metastases. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Response to [(177)Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases
  10. 110
    “…METHODS: Animals received either 3 injections, with a 7-day interval, of vehicle (control group 1), 1200 pmol [(175)Lu]Lu-NeoB (control group 2) or 40 MBq/400 pmol, 80 MBq/800 pmol, and 120 MBq/1200 pmol [(177)Lu]Lu-NeoB (treatment groups 1, 2, and 3, respectively). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety of [(177)Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity
  11. 111
    “…Here we have proven that radiolysed [(177)Lu]Lu-PSMA has less binding affinity and thus likely will influence treatment efficacy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [(177)Lu]Lu-PSMA
  12. 112
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2021: the year [(177)Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines?: Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
  13. 113
    “…$Lu_{3}−_{x}Al_5O_{12}$:Ce optical ceramics ($Lu_3−_{x}AG:Ce,$ x = 1, 2, 3 and 4 at.%, respectively) with $Lu^{3+}$ compositions ranging from 1 to 4 at.% below stoichiometry content were fabricated by solid state reaction method and further optimized by an air-annealing process. …”
    Enlace del recurso
    Enlace del recurso
    Effect of reducing $Lu^{3+}$ content on the fabrication and scintillation properties of non-stoichiometric $Lu_{3}−_{x}Al_5O_{12}$:Ce ceramics
  14. 114
    “…The presented study aims to assess the change in uptake to reference organs, including the liver, parotid and salivary glands after radioligand therapy (RLT) with [(177)Lu]Lu-PSMA-617 in relation to pretreatment imaging metrics. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Impact of [(177)Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [(68)Ga]Ga-PSMA-11-PET/CT
  15. 115
    “…Our aim was to evaluate the efficacy and safety of a repeat (177)Lutetium-[DOTA°,Tyr(3)]octreotate ([(177)Lu]Lu-DOTA-TATE) PRRT course in patients with progressive NET after the first [(177)Lu]Lu-DOTA-TATE PRRT (peptide receptor radionuclide therapy first treatment (PRRT1)). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy, Toxicity, and Prognostic Factors of Re-treatment With [177Lu]Lu-DOTA-TATE in Patients With Progressing Neuroendocrine Tumors: The Experience of a Single Center
  16. 116
    “…Lu(3+)/Yb(3+) and Lu(3+)/Er(3+) co-doped Sb(2)Se(3) nanomaterials were synthesized by co-reduction method in hydrothermal condition. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Lu(3+)/Yb(3+) and Lu(3+)/Er(3+) co-doped antimony selenide nanomaterials: synthesis, characterization, and electrical, thermoelectrical, and optical properties
  17. 117
    “…Li(2)SO(4) or (Li(2)SO(4) + SiO(2))-mixture fluxes were used to prepare a Lu(2)O(3):Eu powder phosphor as well as an undoped Lu(2)O(3) utilizing commercial lutetia and europia as starting reagents. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Flux-Aided Synthesis of Lu(2)O(3) and Lu(2)O(3):Eu—Single Crystal Structure, Morphology Control and Radioluminescence Efficiency
  18. 118
    “…Interface materials offer a means to achieve electrical control of ferrimagnetism at room temperature as was recently demonstrated in (LuFeO(3))(m)/(LuFe(2)O(4))(1) superlattices. A challenge to understanding the inner workings of these complex magnetoelectric multiferroics is the multitude of distinct Fe centres and their associated environments. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Site-specific spectroscopic measurement of spin and charge in (LuFeO(3))(m)/(LuFe(2)O(4))(1) multiferroic superlattices
  19. 119
    “…Methods: Unicentric, retrospective analysis of 125 patients with NET undergoing PRRT with [(177)Lu]Lu-DOTATOC (female: 37%; median age: 66 years; G1+G2 NET: 95%). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [(177)Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis
  20. 120
    “…To facilitate clinical trials, fully automated procedures for the radiosyntheses of [(68)Ga]Ga‐PSMA‐11 and [(177)Lu]Lu‐PSMA‐617 were developed from commercially available precursors using the cassette based iPHASE MultiSyn module. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Automated radiosynthesis of [(68)Ga]Ga‐PSMA‐11 and [(177)Lu]Lu‐PSMA‐617 on the iPHASE MultiSyn module for clinical applications
Herramientas de búsqueda: RSS